Vimian Group AB (publ)

OM:VIMIAN Stock Report

Market Cap: SEK 17.7b

Vimian Group Valuation

Is VIMIAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VIMIAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VIMIAN (SEK33.8) is trading below our estimate of fair value (SEK55.67)

Significantly Below Fair Value: VIMIAN is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VIMIAN?

Other financial metrics that can be useful for relative valuation.

VIMIAN key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.4x
Enterprise Value/EBITDA28x
PEG Ratio3.3x

Price to Sales Ratio vs Peers

How does VIMIAN's PS Ratio compare to its peers?

The above table shows the PS ratio for VIMIAN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average10.4x
XVIVO Xvivo Perfusion
20.5x27.5%SEK 13.2b
BACTI B Bactiguard Holding
12.2x13.4%SEK 2.5b
OSSD OssDsign
7.7x23.9%SEK 904.3m
EKTA B Elekta
1.4x6.1%SEK 25.2b
VIMIAN Vimian Group
4.6x12.2%SEK 17.7b

Price-To-Sales vs Peers: VIMIAN is good value based on its Price-To-Sales Ratio (4.6x) compared to the peer average (10.4x).

Price to Earnings Ratio vs Industry

How does VIMIAN's PE Ratio compare vs other companies in the SE Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.0%
 n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a25.0%
 n/an/an/a
No more companies

Price-To-Sales vs Industry: VIMIAN is good value based on its Price-To-Sales Ratio (4.6x) compared to the Swedish Medical Equipment industry average (4.6x).

Price to Sales Ratio vs Fair Ratio

What is VIMIAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VIMIAN PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.6x
Fair PS Ratio6.2x

Price-To-Sales vs Fair Ratio: VIMIAN is good value based on its Price-To-Sales Ratio (4.6x) compared to the estimated Fair Price-To-Sales Ratio (6.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VIMIAN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 33.35
SEK 37.96
+13.8%
17.5%SEK 47.92SEK 27.30n/a7
Jun ’25SEK 34.95
SEK 39.10
+11.9%
18.8%SEK 50.47SEK 27.92n/a7
May ’25SEK 30.30
SEK 39.36
+29.9%
22.5%SEK 51.52SEK 27.13n/a6
Apr ’25SEK 32.50
SEK 38.69
+19.0%
22.5%SEK 50.36SEK 27.01n/a6
Mar ’25SEK 30.24
SEK 39.01
+29.0%
20.8%SEK 49.97SEK 27.84n/a7
Feb ’25SEK 28.68
SEK 37.55
+30.9%
18.8%SEK 48.91SEK 28.20n/a7
Jan ’25SEK 29.60
SEK 37.01
+25.0%
18.8%SEK 47.99SEK 27.67n/a7
Dec ’24SEK 26.28
SEK 38.05
+44.8%
20.3%SEK 48.86SEK 27.33n/a6
Nov ’24SEK 26.02
SEK 42.67
+64.0%
16.8%SEK 49.92SEK 28.43n/a6
Oct ’24SEK 23.84
SEK 44.34
+86.0%
9.9%SEK 49.95SEK 36.97n/a6
Sep ’24SEK 33.08
SEK 44.20
+33.6%
9.9%SEK 49.78SEK 36.84n/a6
Aug ’24SEK 27.26
SEK 43.78
+60.6%
9.1%SEK 50.99SEK 38.12n/a6
Jul ’24SEK 25.60
SEK 44.76
+74.8%
9.0%SEK 51.82SEK 38.74SEK 33.806
Jun ’24SEK 30.76
SEK 43.94
+42.8%
9.5%SEK 49.93SEK 37.33SEK 34.956
May ’24SEK 37.18
SEK 41.31
+11.1%
12.3%SEK 49.86SEK 33.52SEK 30.306
Apr ’24SEK 32.78
SEK 41.17
+25.6%
12.4%SEK 49.57SEK 33.32SEK 32.506
Mar ’24SEK 23.32
SEK 46.55
+99.6%
21.5%SEK 61.90SEK 34.87SEK 30.246
Feb ’24SEK 29.14
SEK 48.27
+65.6%
20.2%SEK 61.87SEK 36.09SEK 28.686
Jan ’24SEK 27.22
SEK 47.31
+73.8%
20.0%SEK 59.64SEK 34.78SEK 29.606
Dec ’23SEK 36.76
SEK 47.31
+28.7%
20.0%SEK 59.64SEK 34.78SEK 26.286
Nov ’23SEK 33.92
SEK 62.85
+85.3%
30.8%SEK 85.78SEK 29.97SEK 26.025
Oct ’23SEK 26.36
SEK 66.70
+153.0%
25.5%SEK 84.95SEK 35.08SEK 23.845
Sep ’23SEK 32.96
SEK 68.84
+108.9%
19.6%SEK 86.88SEK 45.83SEK 33.085
Aug ’23SEK 40.48
SEK 82.45
+103.7%
20.4%SEK 109.92SEK 57.74SEK 27.265
Jul ’23SEK 49.50
SEK 82.72
+67.1%
18.4%SEK 109.84SEK 63.62SEK 25.605

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.